Trial · NCT07029828
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of treatment-emergent adverse events (AEs). | From the time participant signs informed consent/assent, through and including a minimum of 28 calendar days after the last administration of the study intervention (up to approximately 3 years). | |
| Primary | Incidence of Serious Adverse Events (SAEs) and AEs leading to permanent discontinuation from the study. | From the time participant signs informed consent/assent, through and including a minimum of 28 calendar days after the last administration of the study intervention (up to approximately 3 years). | |
| Secondary | Proportion of participants achieving absolute Severity of Alopecia Tool (SALT) score ≤10. | Months 3,6,9,12,15,18,21,24,27,30,33 and 36. | |
| Secondary | Proportion of participants achieving absolute SALT score ≤20. | Months 3,6,9,12,15,18,21,24,27,30,33 and 36. | |
| Secondary | Change from baseline (CFB) in SALT score. | Baseline, Months 3,6,9,12,15,18,21,24,27,30,33 and 36. | |
| Secondary | Proportion of participants achieving at least 2 grade improvement or a score of 3 in eyebrow assessment (EBA) score in participants with an abnormal EBA at baseline. | Months 3,6,9,12,15,18,21,24,27,30,33 and 36. | |
| Secondary | Proportion of participants achieving at least 2 grade improvement or a score of 3 in eyelash assessment (ELA) score in participants with an abnormal ELA at baseline. | Months 3,6,9,12,15,18,21,24,27,30,33 and 36. | |
| Secondary | Proportion of participants achieving Patient Global Impression of Change (PGI-C) response defined as a score of "moderately improved" or "greatly improved". | Months 3,6,9,12,15,18,21,24,27,30,33 and 36. | |
| Secondary | CFB in PROMIS Parent Proxy Anxiety Symptoms T-score. | Baseline, Months 3,6,9,12,15,18,21,24,27,30,33 and 36. | |
| Secondary | CFB in Behavior Rating Inventory of Executive Function (BRIEF®2) T-scores for the 3 index scores (Behavior Regulation Index (BRI), Emotion Regulation Index (ERI), Cognitive Regulation Index (CRI)). | Baseline, Months 3,6,9,12,15,18,21,24,27,30,33 and 36. | |
| Secondary | CFB in modified Children's Dermatology Life Quality Index (CDLQI) total score. | Baseline, Months 3,6,9,12,15,18,21,24,27,30,33 and 36. | |
| Secondary | CFB in Wechsler Intelligence Scale for Children® Fifth Edition (WISC-V). | Baseline, Month 36 | |
| Other | CFB in Patient-Reported Outcomes Measurement Information System (PROMIS) Parent Proxy Depressive Symptoms T-score. | Baseline, Months 3,6,9,12,15,18,21,24,27,30,33 and 36. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07029828/registered